Maxim Group Keeps Their Buy Rating on Femasys (FEMY)
August 12 2022 - 07:45AM
TipRanks
In a report released yesterday, Jason McCarthy from Maxim Group
maintained a Buy rating on Femasys (FEMY - Research Report), with a
price target of $5.00. The company's shares closed yesterday at
$1.91.McCarthy covers the Healthcare sector, focusing on stocks
such as Atossa Therapeutics, Daré Bioscience, and Capricor
Therapeutics. According to TipRanks, McCarthy has an average return
of -38.2% and a 14.81% success rate on recommended stocks. The word
on The Street in general, suggests a Strong Buy analyst consensus
rating for Femasys with a $6.50 average price target, a 240.31%
upside from current levels. In a report released yesterday,
H.C.
https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-femasys-femy?utm_source=advfn.com&utm_medium=referral
Femasys (NASDAQ:FEMY)
Historical Stock Chart
From Apr 2023 to May 2023
Femasys (NASDAQ:FEMY)
Historical Stock Chart
From May 2022 to May 2023